top of page

Search Results

Search this site

658 results found with an empty search

  • Celltrion licenses Kaigene anti-APRIL antibody KG013 for up to $580.5 million

    Celltrion has licensed Kaigene's next-generation anti-APRIL antibody KG013 in a global agreement worth up to $580.5 million plus royalties. The agreement grants Celltrion worldwide development and commercialisation rights to KG013, a preclinical fully human monoclonal antibody engineered for an extended half-life and long-acting subcutaneous administration, initially targeting IgA nephropathy. Kaigene is eligible for up to $580.5 million in aggregate upfront and development, regulatory and commercial milestone payments plus net-sales royalties, while retaining an option to participate in South Korean co-marketing. Field Content Article Type Deals Companies Celltrion; Kaigene Deal Type Exclusive global licensing agreement Licensor Kaigene Licensee Celltrion Licensed Asset KG013 Therapeutic Area Nephrology; autoimmune diseases Initial Target Indication Immunoglobulin A nephropathy Therapeutic Modality Fully human monoclonal antibody Molecular Target APRIL Asset Characteristics Half-life-extended anti-APRIL antibody Intended Administration Long-acting subcutaneous administration Development Stage Preclinical Licensed Rights Worldwide development and commercialisation Territory Global Total Potential Payments Up to $580.5 million in aggregate upfront and milestone payments Upfront Payment Amount not disclosed Milestone Categories Development, regulatory and commercial Royalties Additional net-sales royalties; rates not disclosed South Korean Rights Kaigene retains an option to participate in co-marketing in South Korea Announcement Date 22 October 2026 What Happened Celltrion secured exclusive global rights to Kaigene's investigational anti-APRIL antibody KG013. Why It Matters The agreement expands Celltrion's investigational autoimmune and kidney disease portfolio with a long-acting antibody programme targeting APRIL. Strategic Rationale Celltrion gains access to an early-stage antibody candidate while Kaigene receives potential licensing revenue and retains a South Korean co-marketing option. Previous Collaboration Context This KG013 agreement is a distinct asset-specific transaction rather than a repeat of earlier Celltrion-Kaigene collaborations. Key Takeaway Kaigene may receive up to $580.5 million in combined upfront and milestone payments plus royalties; the upfront amount is undisclosed and KG013 remains preclinical. What to Watch Preclinical development, clinical trial applications, first-in-human studies, IgA nephropathy efficacy and safety data, and licensing milestones. Primary Source Kaigene via PR Newswire Primary Source URL https://www.prnewswire.com/news-releases/kaigene-enters-into-exclusive-global-licensing-agreement-with-celltrion-for-next-generation-anti-april-antibody-kg013-302916925.html Relevant Date 22 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • OpenAI acquires Orchestra Bio to expand AI-powered drug development capabilities

    OpenAI has acquired Orchestra Bio to strengthen its life-sciences AI capabilities and develop agent-based workflows for pharmaceutical research and development. The acquisition adds Orchestra Bio's technology and team to OpenAI's Rosalind life-sciences AI initiative, with a focus on connecting scientific findings to drug development planning, studies and operational execution. Financial terms were not disclosed, and the transaction concerns drug development technology and workflow capabilities rather than the purchase of a therapeutic asset or clinical-stage medicine. Field Content Article Type Deals Acquirer OpenAI Target Orchestra Bio Deal Type Acquisition Transaction Status Acquisition announced Announcement Date 20 October 2026 Industry Life sciences technology; artificial intelligence Technology Focus AI-enabled coordination of biopharmaceutical drug development Acquired Capabilities Technology platform and team supporting development programmes, studies and operational decisions Integration Destination OpenAI Rosalind life-sciences AI capabilities Strategic Focus Agent-based workflows connecting scientific research with development planning and execution Financial Terms Not disclosed Acquisition Consideration Not disclosed Therapeutic Assets Acquired No specific drug assets identified in supplied summary Development Stage Technology and workflow platform; no specific clinical programme identified Geography Not specified in supplied summary What Happened OpenAI acquired Orchestra Bio to expand its AI capabilities for biopharmaceutical research and development. Why It Matters The transaction reflects growing investment in AI systems designed to coordinate complex scientific and operational work across drug development. Strategic Rationale Integrate Orchestra Bio's development workflow technology and expertise with OpenAI's Rosalind life-sciences capabilities. Potential Impact AI-based agents could support coordination of research findings, study planning and development operations if successfully deployed and validated. Key Takeaway OpenAI's Orchestra Bio acquisition expands its life-sciences technology capabilities; no financial consideration or therapeutic asset acquisition was disclosed. What to Watch Product integration, availability of life-sciences workflows, pharmaceutical partnerships and evidence of operational effectiveness. Primary Source OpenAI Primary Source URL https://openai.com/index/openai-to-acquire-orchestra-bio/ Relevant Date 20 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Edwards Lifesciences Pascal Precision system for tricuspid valve repair

    The FDA has approved Edwards Lifesciences' Pascal Precision system for transcatheter repair of severe tricuspid regurgitation, expanding the device's use beyond mitral valve treatment. The Pascal Precision transcatheter edge-to-edge repair system is now authorised for appropriately selected patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, following assessment by a multidisciplinary heart team. The decision represents a new US indication for a structural heart device previously approved for mitral valve repair in 2022, offering an additional minimally invasive treatment option for eligible patients. Field Content Article Type Approvals Company Edwards Lifesciences Medical Device Pascal Precision System Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Expanded device indication approval New Indication Transcatheter treatment of severe tricuspid regurgitation Patient Population Appropriately selected patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy Patient Selection Multidisciplinary heart team assessment Therapeutic Area Cardiology; structural heart disease Device Category Transcatheter valve repair system Procedure Transcatheter edge-to-edge repair Target Valve Tricuspid valve Prior Approved Use Mitral valve repair Prior Approval Year 2022 Clinical Evidence Specific pivotal study outcomes were not provided in supplied summary Geography United States Announcement Date 21 October 2026 What Happened The FDA approved an expanded indication for the Pascal Precision system to treat selected patients with severe tricuspid regurgitation. Why It Matters The approval provides an additional catheter-based treatment option for patients with symptomatic tricuspid valve disease who remain affected despite medical therapy. Potential Impact Eligible patients may have access to a less invasive valve repair approach following specialist heart team evaluation. Key Takeaway Pascal Precision has gained a new FDA-approved tricuspid valve indication distinct from its earlier mitral valve authorisation. What to Watch US availability, clinical adoption, patient selection criteria, long-term durability and real-world outcomes. Primary Source Cardiovascular Business Primary Source URL https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/fda-approves-pascal-precision-system-edwards-lifesciences-tricuspid-valve-repair Relevant Date 21 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • AmplexDiagnostics announces CE-IVD molecular diagnostic technology combining LAMP and CRISPR

    AmplexDiagnostics has announced a CE-IVD molecular diagnostic technology combining LAMP amplification and CRISPR-based detection for potential European diagnostic applications. The technology combines loop-mediated isothermal amplification with CRISPR-based sequence recognition, bringing together two molecular methods intended to support nucleic acid detection in diagnostic testing. The announcement describes the platform as CE-IVD, but the specific assays, intended clinical uses, applicable European conformity framework and diagnostic performance figures were not established in the supplied summary and require confirmation before clinical claims are made. Field Content Article Type Approvals Company AmplexDiagnostics Product Type Molecular diagnostic technology Technology Combined LAMP and CRISPR detection LAMP Definition Loop-mediated isothermal amplification CRISPR Application Sequence-specific nucleic acid detection Regulatory Designation Reported CE-IVD Regulatory Jurisdiction Europe Regulatory Authority European conformity assessment framework; specific notified body not confirmed Regulatory Status CE-IVD described in company announcement; exact conformity documentation not independently confirmed Specific Assays Not specified in supplied summary Intended Clinical Use Not specified in supplied summary Clinical Indications Not confirmed in supplied summary Analytical Performance Not provided in supplied summary Clinical Performance Not provided in supplied summary Applicable Regulatory Framework Specific directive or regulation not confirmed in supplied summary Announcement Date 21 October 2026 What Happened AmplexDiagnostics announced a molecular diagnostic technology combining LAMP amplification with CRISPR-based detection and described it as CE-IVD. Why It Matters Combining isothermal amplification and sequence-specific detection could support development of molecular diagnostic assays if validated for defined clinical uses. Potential Impact The approach may offer additional technical options for diagnostic developers, subject to assay validation and regulatory conformity. Key Takeaway The announcement concerns a LAMP-CRISPR diagnostic technology described as CE-IVD; its exact authorised uses and performance claims remain unconfirmed. What to Watch Manufacturer conformity documentation, intended-use statements, assay performance data, product availability and clinical adoption. Primary Source AmplexDiagnostics announcement via WebDisclosure Primary Source URL https://www.webdisclosure.com/press-release/amplexdiagnostics-etr-new-innovative-molecular-technology-combination-lamp-crispr-as-ce-ivd-lyWhEd4qbhd Relevant Date 21 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Alcon acquires Neurotech Pharmaceuticals for $550 million to expand retinal disease portfolio

    Alcon is acquiring Neurotech Pharmaceuticals for a reported $550 million, adding Encelto and an encapsulated-cell therapy platform to its retinal disease portfolio. The transaction will expand Alcon's ophthalmic therapeutics activities through Neurotech Pharmaceuticals' Encelto product and encapsulated-cell technology, complementing Alcon's established surgical and vision-care businesses. The reported acquisition value is $550 million, although the supplied announcement summary does not specify the consideration structure, closing conditions or a confirmed completion date. Field Content Article Type Deals Acquirer Alcon Target Neurotech Pharmaceuticals Deal Type Acquisition Reported Transaction Value $550 million Transaction Status Acquisition announced; completion status not confirmed in supplied summary Announcement Period 21-22 October 2026 Therapeutic Area Ophthalmology; retinal diseases Key Portfolio Product Encelto Acquired Technology Encapsulated-cell therapy platform Strategic Focus Retinal disease therapeutics Payment Structure Not confirmed in supplied summary Closing Conditions Not confirmed in supplied summary Expected Closing Date Not confirmed in supplied summary Geography Not specified in supplied summary What Happened Alcon announced the acquisition of Neurotech Pharmaceuticals for a reported $550 million. Why It Matters The transaction broadens Alcon's retinal disease portfolio and adds an encapsulated-cell therapy platform to its ophthalmology capabilities. Strategic Rationale Expand beyond Alcon's existing surgical and vision-care businesses into additional retinal therapeutics and drug delivery technologies. Potential Impact The acquired platform may support future development and commercialisation of therapies for retinal diseases. Key Takeaway Alcon's reported $550 million Neurotech acquisition adds Encelto and encapsulated-cell technology; detailed transaction terms remain unconfirmed in the supplied summary. What to Watch Transaction completion, integration of Neurotech, Encelto commercial development and future retinal therapy programmes. Primary Source Eyewire News Primary Source URL https://eyewire.news/news/alcon-acquires-neurotech-pharmaceuticals-for-550-million-adding-encelto-to-retina-portfolio Relevant Date 21-22 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA grants accelerated approval to AstraZeneca Ultomiris for primary IgA nephropathy in adults

    The FDA has granted accelerated approval to AstraZeneca's Ultomiris for adults with primary IgA nephropathy, introducing a C5 complement inhibitor treatment to reduce proteinuria. Ultomiris (ravulizumab-cwvz) targets complement component C5 and has received accelerated approval in the United States to reduce proteinuria in adults with primary immunoglobulin A nephropathy, a rare kidney disease. The decision was supported by the Phase III I CAN programme, which previously reported a 43.4% reduction in proteinuria versus placebo at 34 weeks in a prespecified interim analysis, while the exact label eligibility criteria and confirmatory requirements should be checked against FDA prescribing information. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Accelerated approval Company AstraZeneca Drug Name Ultomiris Generic Name Ravulizumab-cwvz Therapeutic Area Nephrology; rare kidney diseases Indication Reduction of proteinuria in adults with primary immunoglobulin A nephropathy Patient Population Adults with primary IgA nephropathy; additional label eligibility criteria not confirmed in supplied summary Drug Class Complement inhibitor Mechanism of Action Inhibition of complement component C5 Supporting Clinical Study Phase III I CAN Reported Clinical Result 43.4% reduction in proteinuria versus placebo at 34 weeks in a prespecified interim analysis Clinical Endpoint Proteinuria reduction Approval Pathway Accelerated approval Confirmatory Requirements Not specified in supplied summary; consult final FDA prescribing information Geography United States Announcement Date 21 October 2026 What Happened The FDA granted accelerated approval to Ultomiris to reduce proteinuria in adults with primary IgA nephropathy. Why It Matters The decision introduces a complement C5-targeting treatment approach for a rare kidney disease associated with progressive kidney damage. Clinical Evidence The Phase III I CAN programme reported a 43.4% reduction in proteinuria versus placebo at 34 weeks in an interim analysis. Key Takeaway Ultomiris offers a newly authorised complement-inhibition option for reducing proteinuria in primary IgA nephropathy; accelerated approval does not establish confirmed long-term kidney protection. What to Watch Final prescribing information, confirmatory clinical evidence, long-term kidney outcomes, reimbursement and treatment adoption. Primary Source AstraZeneca Primary Source URL https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/ULTOMIRIS-ravulizumab-cwvz-received-accelerated-approval-in-the-US-as-first-and-only-C5-complement-inhibitor-to-reduce-proteinuria-in-adults-with-primary-immunoglobulin-A-nephropathy.html Relevant Date 21 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Astellas signs AI Proteins miniprotein therapeutics collaboration valued at more than $400 million

    Astellas Pharma and AI Proteins have signed a research and licensing agreement worth more than $400 million in potential value to develop novel miniprotein therapeutics. The collaboration will apply AI-enabled computational protein design to the discovery and development of miniprotein-based medicines, combining AI Proteins' technology with Astellas Pharma's therapeutic development capabilities. The companies disclosed potential agreement value exceeding $400 million, but the exact upfront payment, milestone structure, therapeutic targets and development stages were not established in the supplied announcement summary. Field Content Article Type Deals Companies Astellas Pharma; AI Proteins Deal Type Research collaboration and licensing agreement Announcement Date 21 October 2026 Technology Focus AI-enabled computational protein design Therapeutic Modality Miniprotein-based therapeutics Research Objective Discover and develop novel therapeutic miniproteins Potential Agreement Value More than $400 million Upfront Payment Not confirmed in supplied summary Milestone Payments Individual amounts and conditions not confirmed in supplied summary Royalties Not confirmed in supplied summary Therapeutic Targets Not specified in supplied summary Indications Not specified in supplied summary Development Stage Research and discovery; specific programme stages not confirmed Territorial Rights Not confirmed in supplied summary Geography Japan; United States What Happened Astellas Pharma and AI Proteins announced a research collaboration and licence agreement for miniprotein therapeutics. Why It Matters AI-designed miniproteins represent a potential approach to developing new therapeutic molecules with engineered binding and functional properties. Strategic Rationale Combine AI Proteins' computational design capabilities with Astellas Pharma's drug development expertise. Potential Impact The partnership could generate new investigational therapeutic candidates if discovery and development objectives are achieved. Key Takeaway The collaboration has a stated potential value exceeding $400 million; the supplied information does not establish how much is payable upfront or guaranteed. What to Watch Disclosure of therapeutic targets, candidate selection, preclinical validation, milestone achievements and future clinical development. Primary Source AI Proteins via Business Wire Primary Source URL https://www.businesswire.com/news/home/20261021073833/en/AI-Proteins-Announces-Research-Collaboration-and-License-Agreement-With-Astellas-Pharma-to-Discover-and-Develop-Novel-Miniprotein-Based-Therapeutics-Valued-at-Over-%24400-Million Relevant Date 21 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • European Commission approves Keytruda plus Padcev for perioperative treatment of muscle-invasive bladder cancer

    The European Commission has authorised Keytruda plus Padcev before and after surgery for adults with resectable muscle-invasive bladder cancer, expanding perioperative treatment options in the EU. Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) are approved as neoadjuvant treatment before radical cystectomy followed by adjuvant treatment for adults with resectable muscle-invasive bladder cancer, regardless of cisplatin eligibility. In the Phase III KEYNOTE-B15 study involving cisplatin-eligible patients, the combination reduced the risk of disease progression, recurrence or death by 47% and the risk of death by 35% compared with neoadjuvant gemcitabine-cisplatin and surgery. Field Content Article Type Approvals Regulatory Authority European Commission Regulatory Decision Marketing authorisation Company Merck & Co.; Padcev development and commercialisation partners not specified in supplied summary Drug Combination Keytruda plus Padcev Drug Names Pembrolizumab; enfortumab vedotin Therapeutic Area Oncology; bladder cancer Approved Indication Perioperative treatment of adults with resectable muscle-invasive bladder cancer Patient Population Adults with resectable muscle-invasive bladder cancer regardless of cisplatin eligibility Treatment Sequence Neoadjuvant Keytruda plus Padcev before radical cystectomy followed by adjuvant treatment Supporting Study Phase III KEYNOTE-B15 Study Comparison Combination regimen versus neoadjuvant gemcitabine-cisplatin and surgery Study Population Cisplatin-eligible patients Progression Recurrence or Death Risk Reduction 47% relative risk reduction Overall Survival Risk Reduction 35% relative reduction in risk of death Geography European Union Announcement Date 21 October 2026 What Happened The European Commission authorised perioperative Keytruda plus Padcev for adults with resectable muscle-invasive bladder cancer. Why It Matters The approval expands access to an immunotherapy and antibody-drug conjugate combination in the potentially curative treatment setting. Clinical Evidence KEYNOTE-B15 reported improved disease-related and survival outcomes against a chemotherapy-based comparator in cisplatin-eligible patients. Key Takeaway The new EU authorisation covers perioperative treatment regardless of cisplatin eligibility; the supplied efficacy figures come from a cisplatin-eligible trial population. What to Watch European reimbursement decisions, clinical guideline adoption, treatment uptake and longer-term outcomes. Primary Source Merck & Co. Primary Source URL https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-resectable-muscle-invasive-bladder-cancer-mibc/ Relevant Date 21 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA finalises guidance on prescription drug companion apps and software labelling

    The FDA has issued final guidance clarifying how prescription drug manufacturers should address companion apps and software in product labelling and regulatory submissions. The guidance explains regulatory expectations for software distributed alongside prescription medicines, including when app content may constitute required or promotional labelling and when companion software should be reflected in prescribing information. It also addresses submission expectations and distinctions between device-connected applications and standalone tools such as medication reminders, symptom trackers and patient coaching software, giving pharmaceutical and digital health developers a clearer regulatory framework. Field Content Article Type Industry Updates Regulatory Authority U.S. Food and Drug Administration Jurisdiction United States Policy Type Final regulatory guidance Guidance Topic Prescription drug companion apps and software Guidance Announcement Date 20 October 2026 Regulatory Status Final guidance Affected Sectors Pharmaceuticals; biotechnology; digital health; healthcare software Affected Products Prescription medicines distributed with companion apps or software Key Regulatory Area Prescription drug labelling and software-related regulatory submissions Labelling Considerations When companion software content constitutes required or promotional labelling Prescribing Information Circumstances in which companion software should be addressed in official prescribing information Submission Considerations Materials manufacturers should provide to the FDA regarding relevant companion software Device-Connected Applications Guidance distinguishes applications connected to medical devices from other software tools Standalone Software Examples Medication reminders; symptom trackers; patient coaching tools Legal Status Final agency guidance; not a new product marketing authorisation What Happened The FDA issued final guidance addressing regulatory expectations for prescription drug apps and companion software. Why It Matters Pharmaceutical manufacturers increasingly offer digital tools alongside medicines and need clarity on labelling, promotional communications and regulatory submission expectations. Industry Implications Drug developers and digital health partners may need to review companion software content and associated regulatory documentation against the final guidance. Potential Impact Clearer regulatory expectations may support more consistent development and communication of digital tools associated with prescription medicines. Key Takeaway The FDA has finalised guidance on prescription drug companion software, clarifying labelling and submission considerations for pharmaceutical and digital health companies. What to Watch Industry implementation, updates to product labelling practices, regulatory submissions and further FDA clarification. Primary Source U.S. Food and Drug Administration Primary Source URL https://www.fda.gov/news-events/press-announcements/fda-issues-final-guidance-prescription-drug-apps-and-software Relevant Date 20 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Ambrose Healthcare acquires AM-Pharma in rare disease transaction worth up to €161 million

    Ambrose Healthcare has acquired Netherlands-based AM-Pharma in a rare disease transaction worth up to €161 million, adding an investigational therapy for hypophosphatasia. The acquisition gives Ambrose full ownership of AM-Pharma, its Phase II-ready ilofotase alfa programme and a European operating base in Utrecht, expanding the company's rare disease development activities. Former AM-Pharma shareholders are eligible for an upfront payment, commercialisation-linked milestones and royalties on future sales, although the individual payment amounts have not been disclosed and the maximum transaction consideration remains contingent. Field Content Article Type Deals Companies Ambrose Healthcare; AM-Pharma Deal Type Acquisition Acquirer Ambrose Healthcare Target AM-Pharma Target Country Netherlands Ownership Acquired 100% Transaction Status Acquisition announced as completed Announcement Date 20 October 2026 Maximum Transaction Consideration Up to €161 million Payment Structure Upfront payment plus commercialisation-linked milestones Upfront Payment Amount not disclosed in supplied summary Milestone Payments Commercialisation-linked; individual amounts not disclosed Royalties Royalties on future sales; rates not disclosed Key Pipeline Asset Ilofotase alfa Key Asset Development Stage Phase II-ready Key Asset Indication Hypophosphatasia Therapeutic Area Rare diseases; metabolic bone disorders European Operating Base Utrecht, Netherlands Geography Netherlands; Europe What Happened Ambrose Healthcare acquired 100% of AM-Pharma in a transaction with potential consideration of up to €161 million. Why It Matters The acquisition adds an investigational rare disease treatment programme and establishes a European operating presence for Ambrose Healthcare. Strategic Rationale Ambrose aims to expand its rare disease pipeline and European development capabilities through the acquisition. Potential Impact The transaction may support further clinical development of ilofotase alfa for hypophosphatasia. Key Takeaway Ambrose has acquired AM-Pharma and its Phase II-ready ilofotase alfa programme; the maximum €161 million consideration includes contingent payments. What to Watch Ilofotase alfa Phase II development plans, clinical trial initiation, regulatory interactions and future commercialisation milestones. Primary Source Ambrose Healthcare Primary Source URL https://www.ambrosehc.com/news/ambrose-healthcare-acquires-am-pharma-for-up-to-%E2%82%AC161-million-expanding-its-rare-disease-pipeline-and-gaining-a-european-base Relevant Date 20 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Eli Lilly partners with METiS TechBio in AI-driven lipid nanoparticle collaboration worth up to $1.1 billion in milestones

    Eli Lilly and METiS TechBio have entered an AI-enabled lipid nanoparticle discovery collaboration carrying up to approximately $1.1 billion in potential milestone payments. The partnership will use METiS TechBio's AiLNP platform to discover and optimise ionizable lipids for tissue-specific lipid nanoparticle delivery, with the aim of improving the targeting and biodistribution of therapeutic modalities. METiS is eligible for an upfront payment in the low double-digit millions of US dollars and approximately $1.1 billion in contingent development, regulatory and commercial milestones, while the technology remains at the research stage. Field Content Article Type Deals Companies Eli Lilly; METiS TechBio Deal Type Strategic research collaboration Announcement Date 19 October 2026 Technology Focus AI-driven lipid nanoparticle discovery and optimisation Technology Platform METiS AiLNP platform Research Focus Tissue-specific lipid nanoparticle delivery technologies Key Technology Component Ionizable lipid discovery and optimisation Therapeutic Application Delivery and biodistribution of therapeutic modalities Upfront Payment Low double-digit millions of US dollars; exact amount not disclosed in supplied summary Potential Milestone Payments Up to approximately $1.1 billion Milestone Categories Development; regulatory; commercial Total Potential Deal Value Upfront payment plus up to approximately $1.1 billion in contingent milestones Royalties Not confirmed in supplied summary Geography United States; Hong Kong Development Stage Research and discovery Clinical Status No clinical efficacy established by this collaboration announcement What Happened Eli Lilly entered a strategic research collaboration with METiS TechBio to develop tissue-specific lipid nanoparticle delivery technologies using AI. Why It Matters More precise delivery technologies could help address limitations in how therapeutic molecules reach intended tissues. Strategic Rationale Lilly gains access to METiS's AI-enabled nanoparticle discovery capabilities while METiS receives upfront funding and potential milestone opportunities. Potential Impact The collaboration could support future development of targeted delivery technologies if research objectives are achieved. Key Takeaway The agreement includes an upfront payment in the low double-digit millions and up to approximately $1.1 billion in contingent milestones, not guaranteed transaction proceeds. What to Watch Research milestones, delivery platform validation, programme selection, preclinical results and potential clinical development. Primary Source METiS TechBio Primary Source URL https://metistechbio.com/en/qyxw/253.html Relevant Date 19 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves GSK Hibsago bepirovirsen as first antisense treatment for chronic hepatitis B

    The FDA has approved GSK's Hibsago as the first antisense oligonucleotide treatment for chronic hepatitis B, offering eligible patients a new approach to sustained viral control. Hibsago (bepirovirsen) is authorised alongside nucleos(t)ide analogue antiviral therapy for adults without cirrhosis who have received antiviral treatment for at least six months, have suppressed hepatitis B viral DNA and have HBsAg levels no higher than 3000 IU/mL. The approval introduces a treatment with a different mechanism from conventional antivirals and offers the possibility of sustained viral control after treatment discontinuation for some eligible patients, although individual outcomes and follow-up requirements remain important. Field Content Article Type Approvals Drug Name Hibsago Generic Name Bepirovirsen Company GSK Regulatory Authority U.S. Food and Drug Administration Regulatory Decision New drug approval Approval Announcement Date 20 October 2026 Indication Chronic hepatitis B in eligible adults Patient Population Adults without cirrhosis who have received nucleos(t)ide analogue antiviral therapy for at least six months, have suppressed HBV DNA and have HBsAg levels no higher than 3000 IU/mL Therapeutic Area Infectious diseases; hepatology Drug Class Antisense oligonucleotide Treatment Regimen Used alongside nucleos(t)ide analogue antiviral therapy Prior Treatment Requirement At least six months of antiviral treatment Viral Suppression Requirement Suppressed hepatitis B viral DNA HBsAg Eligibility Threshold No higher than 3000 IU/mL Cirrhosis Restriction Adults without cirrhosis Approval Significance First approved antisense oligonucleotide treatment for chronic hepatitis B Potential Treatment Benefit Possibility of sustained viral control after stopping treatment for some eligible patients Clinical Evidence Specific pivotal study results and efficacy percentages were not provided in the supplied summary Geography United States What Happened The FDA approved GSK's Hibsago bepirovirsen for eligible adults with chronic hepatitis B. Why It Matters The approval introduces an antisense treatment approach for a chronic viral infection that commonly requires prolonged antiviral management. Potential Impact Eligible patients may gain an additional treatment option with the potential for sustained viral control after therapy. Key Takeaway Hibsago is a newly approved antisense treatment for selected adults with chronic hepatitis B, subject to defined antiviral treatment and laboratory eligibility requirements. What to Watch US prescribing guidance, treatment availability, reimbursement, sustained treatment-response data and longer-term safety outcomes. Primary Source U.S. Food and Drug Administration Primary Source URL https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment Relevant Date 20 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page